COPENHAGEN, DENMARK (Reuters) -Shares in Wegovy maker Novo Nordisk (NVO, NOVO-B.CO)continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker’s value. Novo Nordisk on Tuesday slashed…
Hims & Hers Health has experienced a tumultuous quarter, marked by Novo Nordisk’s termination of their collaboration after allegations of unsafe practices, resulting in a 35% drop in the company’s share price. This partnership termination, alongside a class action lawsuit alleging misleading statements about safety and operational risks, contributed to heightened market volatility. Despite a…
© 2025 Bloomberg Finance LP Hims & Hers cofounder and CEO Andrew Dudum dropped out of Forbes’ billionaire ranks on Monday – less than two months after joining the three-comma-club, in May. Dudum, 36, lost more than $400 million in wealth in a single trading day, after shares of his telehealth firm, known for its…
Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm’s weight-loss drug, Wegovy. The Danish drugmaker said Monday that Wegovy will no longer be available on Hims & Hers and that it is ending the collaboration because the San…